Johnson & Johnson (JNJ)
154.00
+2.13
(+1.40%)
USD |
NYSE |
Nov 15, 16:00
154.10
+0.10
(+0.06%)
Pre-Market: 20:00
Johnson & Johnson Research and Development Expense (TTM): 16.41B for Sept. 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | 16.41B |
| June 30, 2024 | 14.91B |
| March 31, 2024 | 15.17B |
| December 31, 2023 | 15.08B |
| September 30, 2023 | 14.32B |
| June 30, 2023 | 14.35B |
| March 31, 2023 | 14.35B |
| December 31, 2022 | 14.97B |
| September 30, 2022 | 15.54B |
| June 30, 2022 | 15.48B |
| March 31, 2022 | 15.17B |
| December 31, 2021 | 14.28B |
| September 30, 2021 | 14.21B |
| June 30, 2021 | 13.62B |
| March 31, 2021 | 12.94B |
| December 31, 2020 | 12.34B |
| September 30, 2020 | 11.36B |
| June 30, 2020 | 11.12B |
| March 31, 2020 | 11.08B |
| December 31, 2019 | 11.36B |
| September 30, 2019 | 11.35B |
| June 30, 2019 | 11.26B |
| March 31, 2019 | 11.23B |
| December 31, 2018 | 10.78B |
| September 30, 2018 | 11.19B |
| Date | Value |
|---|---|
| June 30, 2018 | 11.27B |
| March 31, 2018 | 10.93B |
| December 31, 2017 | 10.59B |
| September 30, 2017 | 9.639B |
| June 30, 2017 | 9.232B |
| March 31, 2017 | 9.20B |
| December 31, 2016 | 9.143B |
| September 30, 2016 | 9.319B |
| June 30, 2016 | 9.295B |
| March 31, 2016 | 9.16B |
| December 31, 2015 | 9.046B |
| September 30, 2015 | 8.817B |
| June 30, 2015 | 8.686B |
| March 31, 2015 | 8.562B |
| December 31, 2014 | 8.494B |
| September 30, 2014 | 8.27B |
| June 30, 2014 | 8.289B |
| March 31, 2014 | 8.23B |
| December 31, 2013 | 8.183B |
| September 30, 2013 | 8.103B |
| June 30, 2013 | 7.984B |
| March 31, 2013 | 7.804B |
| December 31, 2012 | 7.665B |
| September 30, 2012 | 7.489B |
| June 30, 2012 | 7.339B |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
11.08B
Minimum
Mar 2020
16.41B
Maximum
Sep 2024
13.90B
Average
14.33B
Median
Research and Development Expense (TTM) Benchmarks
| Amgen Inc | 5.774B |
| Eli Lilly and Co | 10.53B |
| Merck & Co Inc | 22.98B |
| Pfizer Inc | 10.60B |
| AbbVie Inc | 8.722B |